S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Evogene Stock Forecast, Price & News

+0.01 (+0.50%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
152,220 shs
Average Volume
758,297 shs
Market Capitalization
$52.27 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Evogene logo

About Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agrobiological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.


Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 33.2% in October
November 19, 2021 |  americanbankingnews.com
Evogene (NASDAQ:EVGN) Issues Earnings Results
November 17, 2021 |  americanbankingnews.com
Evogene Reports Third Quarter 2021 Financial Results
November 17, 2021 |  finance.yahoo.com
Analyzing Save Foods (NASDAQ:SVFD) and Evogene (NASDAQ:EVGN)
November 8, 2021 |  americanbankingnews.com
Evogene (EVGN) Launches result - StreetInsider.com
November 3, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Agricultural chemicals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.04 million
Book Value
$2.75 per share


Net Income
$-23.37 million
Net Margins
Pretax Margin




Free Float
Market Cap
$52.27 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.78 out of 5 stars

Medical Sector

844th out of 1,391 stocks

Agricultural Chemicals Industry

9th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Evogene (NASDAQ:EVGN) Frequently Asked Questions

Is Evogene a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evogene stock.
View analyst ratings for Evogene
or view top-rated stocks.

How has Evogene's stock been impacted by COVID-19 (Coronavirus)?

Evogene's stock was trading at $0.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVGN stock has increased by 105.1% and is now trading at $2.03.
View which stocks have been most impacted by COVID-19

Are investors shorting Evogene?

Evogene saw a decline in short interest during the month of October. As of October 29th, there was short interest totaling 551,100 shares, a decline of 33.2% from the October 14th total of 825,300 shares. Based on an average daily volume of 332,400 shares, the short-interest ratio is currently 1.7 days. Approximately 1.5% of the company's stock are short sold.
View Evogene's Short Interest

When is Evogene's next earnings date?

Evogene is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Evogene

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings data on Tuesday, November, 16th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02. Evogene had a negative net margin of 3,013.61% and a negative trailing twelve-month return on equity of 40.83%. During the same period in the previous year, the company posted ($0.17) earnings per share.
View Evogene's earnings history

What price target have analysts set for EVGN?

4 brokers have issued 1 year price targets for Evogene's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Evogene's stock price to reach $8.25 in the next year. This suggests a possible upside of 306.4% from the stock's current price.
View analysts' price targets for Evogene
or view top-rated stocks among Wall Street analysts.

Who are Evogene's key executives?

Evogene's management team includes the following people:
  • Ofer Haviv, President & Chief Executive Officer
  • Dorit Kreiner, Chief Financial Officer
  • Mark Kapel, Executive Vice President-Technology
  • Eyal Emmanuel, Chief Scientific Officer
  • Nir Arbel, Chief Product Officer

What other stocks do shareholders of Evogene own?

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

Who are Evogene's major shareholders?

Evogene's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.78%), Renaissance Technologies LLC (1.03%), Senvest Management LLC (0.90%), Citadel Advisors LLC (0.00%), LPL Financial LLC (0.28%) and Geode Capital Management LLC (0.23%).

Which major investors are selling Evogene stock?

EVGN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Senvest Management LLC, Citadel Advisors LLC, Squarepoint Ops LLC, Jump Financial LLC, Jane Street Group LLC, UBS Group AG, and Goldman Sachs Group Inc..

Which major investors are buying Evogene stock?

EVGN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vident Investment Advisory LLC, Geode Capital Management LLC, Susquehanna International Group Ltd., Crestwood Advisors Group LLC, LPL Financial LLC, and Csenge Advisory Group.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $2.03.

How much money does Evogene make?

Evogene has a market capitalization of $52.27 million and generates $1.04 million in revenue each year. The biotechnology company earns $-23.37 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Evogene have?

Evogene employs 131 workers across the globe.

What is Evogene's official website?

The official website for Evogene is www.evogene.com.

Where are Evogene's headquarters?

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at (728) 931-1900, via email at [email protected], or via fax at 972-8946-6724.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.